BioSpace News Archive

Verseau Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for its lead investigational product candidate, VTX-0811, a monoclonal antibody that binds to P-selectin glycoprotein ligand-1 (PSGL-1).

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

Twist Bioscience Corporation (NASDAQ: TWST), today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 4:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.

Equillium, Inc. (Nasdaq: EQ), today announced that the Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective of safety and tolerability and demonstrated on-target peak and sustained reduction of CD6 at Day 85 (one month following last dose).

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time.

Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022.

NLS Pharmaceutics Ltd. announces that the United States Patent and Trademark Office has granted the Company U.S. Patent No. 11207271, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 12:45 p.m. Pacific Time/3:45 p.m. Eastern Time.

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President, Business Development.